Future oncology最新文献

Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer.

IF 3 4区医学

Future oncology Pub Date : 2024-12-23 DOI: 10.1080/14796694.2024.2442900

Hayley Nicole Roberts, Corinne Maurice-Dror, Kim Nguyen Chi

{"title":"Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer.","authors":"Hayley Nicole Roberts, Corinne Maurice-Dror, Kim Nguyen Chi","doi":"10.1080/14796694.2024.2442900","DOIUrl":"https://doi.org/10.1080/14796694.2024.2442900","url":null,"abstract":"Metastatic prostate cancer remains incurable. Though significant progress has been made in the field, the search for agents that improve outcomes for patients is ongoing. Several clinical trials have explored the benefit of combining PARP inhibitors (PARPi) with androgen receptor pathway inhibitors (ARPIs) for metastatic castrate resistant prostate cancer (mCRPC), especially those cancers with alterations in homologous recombination repair (HRR) genes. Niraparib, a highly selective inhibitor of PARP1 and PARP2, has been shown to confer a radiographic progression-free survival benefit in the treatment of mCRPC with HRR-associated gene alterations, particularly BRCA1 and BRCA2 (BRCA1/2), when combined with abiraterone acetate plus prednisolone (AAP). This combination has recently been approved in the USA, Canada and Europe for patients with mCRPC and a BRCA1/2 gene mutation. This review summarizes the evidence with regards to the pharmacologic activity and clinical efficacy of niraparib with a specific focus on its efficacy in combination with AAP in mCRPC patients with HRR alterations.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker?

IF 3 4区医学

Future oncology Pub Date : 2024-12-23 DOI: 10.1080/14796694.2024.2444862

Antoine Mouawad, Marc Boutros, Antoine Chartouni, Fouad Attieh, Hampig Raphaël Kourie

引用次数: 0

A nomogram with coagulation markers for prostate cancer prediction in patients with PSA levels of 4-20 ng/mL.

IF 3 4区医学

Future oncology Pub Date : 2024-12-23 DOI: 10.1080/14796694.2024.2445499

Feifan Liu, Jianyu Wang, Yufeng Song, Fei Wu, Haihu Wu, Jiaju Lyu, Hao Ning

{"title":"A nomogram with coagulation markers for prostate cancer prediction in patients with PSA levels of 4-20 ng/mL.","authors":"Feifan Liu, Jianyu Wang, Yufeng Song, Fei Wu, Haihu Wu, Jiaju Lyu, Hao Ning","doi":"10.1080/14796694.2024.2445499","DOIUrl":"https://doi.org/10.1080/14796694.2024.2445499","url":null,"abstract":"Background: The global incidence of prostate cancer (PCa) is rising, necessitating improved diagnostic strategies. This study explores coagulation parameters' predictive value for clinically significant PCa (csPCa) and develops a nomogram.Research design and methods: This study retrospectively analyzed data from 702 patients who underwent prostate biopsy at Shandong Provincial Hospital (SDPH) and 142 patients at Shandong Cancer Hospital and Institute (SDCHI). SDPH patients were randomly assigned at a 7:3 ratio for internal validation, while SDCHI data served as external validation. LASSO and logistic regression identified the best predictive factors for csPCa, which were used to construct a model. The model's efficacy was tested using AUC, calibration curves, and decision curve analysis.Results: TPSA, age, D-dimer, prostate volume (PV), and digital rectal examination (DRE) were identified as independent risk factors for csPCa. A predictive model was constructed using a nomogram. The AUC for the training set was 0.841, for internal validation 0.809, and for external validation 0.814. Calibration and decision curves confirmed the model's clinical utility.Conclusions: The nomogram incorporating D-dimer, TPSA, age, PV, and DRE provides a highly accurate tool for assessing csPCa risk in individuals with PSA levels of 4-20 ng/mL, supporting personalized diagnostics and clinical decision-making.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-9"},"PeriodicalIF":3.0,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan.

IF 3 4区医学

Future oncology Pub Date : 2024-12-20 DOI: 10.1080/14796694.2024.2441649

Takahiro Nakayama, Linghua Xu, Yasuaki Muramatsu

{"title":"CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan.","authors":"Takahiro Nakayama, Linghua Xu, Yasuaki Muramatsu","doi":"10.1080/14796694.2024.2441649","DOIUrl":"https://doi.org/10.1080/14796694.2024.2441649","url":null,"abstract":"Background: Though efforts have been made toward standardizing access to quality cancer care in Japan, there are still geographical and institutional disparities in the level of cancer care availability. We investigated the utilization of cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy (CDK4/6i+ET) as first-line (1 L) treatment for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in Japan.Research design and methods: This cross-sectional survey included physicians who had treated ≥3 1 L patients with HR+/HER2- ABC in the past year.Results: Of 41,695 physicians invited, 300 were included in the analysis. The mean percentage share of CDK4/6i+ET and ET monotherapy was 38.3% and 42.2%, respectively. Common challenges facing CDK4/6i+ET prescription were adverse reaction management, prohibitive cost, and a preference for ET monotherapy for treating elderly patients. Key solutions included reducing the burden of adverse reaction management, improving financial support, and preparing educational videos for medical staff.Conclusions: The study concluded that CDK4/6i+ET is not well established as a 1 L option in Japan as of 2022. More effective ways of creating awareness and supportive tools are needed for CDK4/6i+ET to be adopted as standard of care in Japan.Trial registration number: UMIN000050760.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction.

IF 3 4区医学

Future oncology Pub Date : 2024-12-20 DOI: 10.1080/14796694.2024.2445908

引用次数: 0

METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.

IF 3 4区医学

Future oncology Pub Date : 2024-12-20 DOI: 10.1080/14796694.2024.2442296

Jialing Zhao, Ruiqi Sun, Liang Zhi, Danjing Guo, Sunbin Ling, Xiangnan Liang, Jianhui Li, Changku Jia

{"title":"METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.","authors":"Jialing Zhao, Ruiqi Sun, Liang Zhi, Danjing Guo, Sunbin Ling, Xiangnan Liang, Jianhui Li, Changku Jia","doi":"10.1080/14796694.2024.2442296","DOIUrl":"https://doi.org/10.1080/14796694.2024.2442296","url":null,"abstract":"Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths, with high rates of postoperative recurrence. Identifying reliable biomarkers for predicting recurrence is critical for improving patient outcomes. This study investigates the predictive value of m6A methylation-related genes, METTL4 and METTL5, on HCC recurrence after surgery.Research design and methods: We analyzed METTL4 and METTL5 expression in HCC and adjacent non-cancerous tissues using the TCGA database and evaluated their levels in surgical samples from 67 hCC patients. A recurrence risk model was developed and validated in an external cohort of 65 patients.Results: METTL4 and METTL5 were significantly overexpressed in HCC tissues. High expression correlated with shorter recurrence-free survival (RFS). The model stratified patients into high, medium, and low-risk groups with 3-year RFS rates of 18.75%, 69.70%, and 93.75%, respectively.Conclusions: METTL4 and METTL5 expression levels are strong predictors of HCC recurrence. The risk model offers a novel approach for postoperative management of HCC.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma.

IF 3 4区医学

Future oncology Pub Date : 2024-12-18 DOI: 10.1080/14796694.2024.2435247

Guangming Yi, Fanghao Cai, Liangzhong Liu, Rongxin Liao, Xuan Jiang, Zhenzhou Yang, Xiaoyue Zhang

{"title":"Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma.","authors":"Guangming Yi, Fanghao Cai, Liangzhong Liu, Rongxin Liao, Xuan Jiang, Zhenzhou Yang, Xiaoyue Zhang","doi":"10.1080/14796694.2024.2435247","DOIUrl":"https://doi.org/10.1080/14796694.2024.2435247","url":null,"abstract":"Background: The co-occurrence of PD-L1 positivity and EGFR mutations in advanced NSCLC often limits EGFR-TKIs effectiveness, with unclear mechanisms.Methods: We analyzed 103 treatment-naive EGFR-mutant LUAD patients from three centers, assessing PD-L1 expression and performing NGS analysis.Results: SMO mutations and MET amplification were significantly higher in the PD-L1 ≥ 1% group versus PD-L1 < 1% group (SMO: 8% vs. 0%, p = 0.048; MET: 18% vs. 7%, p = 0.023). The DNA Damage Response and Repair (DDR) pathogenic deficiency mutations, along with biological processes and signaling pathways related to DNA recombination, cell cycle transition and abnormal phosphorylation, were more prevalent in the PD-L1 ≥ 1% group. PIK3CA and RARA clonal alterations were more common in PD-L1 < 1% group, while TP53 clonal mutations predominated in PD-L1 ≥ 1% group. Retrospective analysis showed EGFR-TKIs plus chemotherapy extended median PFS by 9.8 months, potentially overcoming EGFR-TKI monotherapy resistance.Conclusion: This study elucidates the genomic characteristics of PD-L1-induced resistance to EGFR-TKIs. For patients with concurrent mutations in EGFR and PD-L1 expression, a first-line treatment strategy combining EGFR-TKIs with chemotherapy may offer a more effective alternative.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-14"},"PeriodicalIF":3.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Earlier versus delayed ruxolitinib treatment for patients with myelofibrosis: a plain language summary.

IF 3 4区医学

Future oncology Pub Date : 2024-12-18 DOI: 10.1080/14796694.2024.2440255

Claire Harrison, Jean-Jacques Kiladjian, Alessandro M Vannucchi, Ruben A Mesa

引用次数: 0

Decoding clinical trial jargon: helping people understand the efficacy end points used in cancer trials.

IF 3 4区医学

Future oncology Pub Date : 2024-12-18 DOI: 10.1080/14796694.2024.2433411

Marty Henley, Gissoo DeCotiis, Hannah FitzGibbon, Eric K Singhi

引用次数: 0

An early economic evaluation of active surveillance for low-risk ductal carcinoma in situ. 对低风险导管原位癌主动监测的早期经济评估。